Spectrum PharmaceuticalsIRS: 930979187
Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations.
1987 (36 years)